An Update on the Comparative Effectiveness and Safety of Medications for Type 2 Diabetes
Authors: Mark R. Goldstein, Luca Mascitelli
Journal: Annals of Internal Medicine (2011)

Letters18 October 2011An Update on the Comparative Effectiveness and Safety of Medications for Type 2 DiabetesMark R. Goldstein, MD and Luca Mascitelli, MDMark R. Goldstein, MDFrom NCH Healthcare Group, Naples, FL 34109, and Comando Brigata Alpina “Julia”, 33100 Udine, Italy.Search for more papers by this author and Luca Mascitelli, MDFrom NCH Healthcare Group, Naples, FL 34109, and Comando Brigata Alpina “Julia”, 33100 Udine, Italy.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-8-201110180-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We concur with the recent article by Bennett and colleagues (1) that metformin should be the preferred first-line therapy for type 2 diabetes. However, important safety issues regarding dipeptidyl peptidase-4 (DPP-4) inhibitors have recently emerged (2), bolstering disturbing signals raised several years ago in premarket studies with these agents. It is therefore disconcerting that the American Association of Clinical Endocrinologists and the American College of Endocrinology recommend treatment with a DPP-4 inhibitor as an option for initial monotherapy of type 2 diabetes (1).Examination of the U.S. Food and Drug Administration (FDA) database of reported adverse events ...References1. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:602-13. [PMID: 21403054] LinkGoogle Scholar2. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150-6. [PMID: 21334333] CrossrefMedlineGoogle Scholar3. Stulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract. 2010;88:125-31. [PMID: 2030361] CrossrefMedlineGoogle Scholar4. Center for Drug Evaluation and Research. Application Number 21-995: Medical Review. Silver Spring, MD: U.S. Food and Drug Administration; Accessed at www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_MedR.pdf on 7 May 2011. Google Scholar5. European Medicines Agency. Januvia: EPAR—Scientific Discussion. London: European Medicines Agency; 2007. Accessed at www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000722/WC500039057.pdf on 7 May 2011. Google Scholar Author, Article, and Disclosure InformationAffiliations: From NCH Healthcare Group, Naples, FL 34109, and Comando Brigata Alpina “Julia”, 33100 Udine, Italy.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations Wendy L. Bennett , Nisa M. Maruthur , Sonal Singh , Jodi B. Segal , Lisa M. Wilson , Ranee Chatterjee , Spyridon S. Marinopoulos , Milo A. Puhan , Padmini Ranasinghe , Lauren Block , Wanda K. Nicholson , Susan Hutfless , Eric B. Bass , and Shari Bolen An Update on Comparative Effectiveness and Safety of Medications for Type 2 Diabetes Wendy L. Bennett , Sonal Singh , and Jodi B. Segal Metrics 18 October 2011Volume 155, Issue 8Page: 562-563KeywordsDrugsPancreasPancreatic cancerPathogenesisSafetySafety studiesStatistical dataType 2 diabetes ePublished: 18 October 2011 Issue Published: 18 October 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...